Don’t buy into biotech’s ‘drug dream’ recovery

No one sounds all that happy about stocks these days, even as the S&P keeps trying to impress. Our call of the day is certainly skeptical, suggesting investors shouldn’t get fooled by the biotech sector’s bounce-back.